Jae S Ahn

US Patent:

20230110648, Apr 13, 2023

Filed:

Jun 17, 2022

Appl. No.:

17/843769

Inventors:

- Watertown MA, US
Martin Duplessis - Somerville MA, US
Jae Young Ahn - Somerville MA, US
Alexander W. Hird - Belmont MA, US
Ryan E. Michael - Erie CO, US
Kiel Lazarski - Boston MA, US
Yanke Liang - Belmont MA, US
Georg Jaeschke - Basel, CH
Antonio Ricci - Biel-Benken, CH
Annick Goergler - Colmar, FR
Daniel Rueher - Raedersdorf, FR

Assignee:

C4 Therapeutics, Inc. - Watertown MA

International Classification:

C07D 519/00
C07D 487/04
A61K 9/20
A61K 9/48
A61K 9/02
A61K 9/08
A61K 47/10
A61K 47/12
A61K 9/00
A61K 47/26
A61K 47/38
A61K 47/32

Abstract:

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

US Patent:

20200197391, Jun 25, 2020

Filed:

Dec 20, 2019

Appl. No.:

16/723438

Inventors:

- Redwood City CA, US
Nicholas PERL - Somerville MA, US
Anna KOHLMANN - Winchester MA, US
Ning YIN - Lexington MA, US
Jason T. LOWE - East Bridgewater MA, US
Jae Young AHN - Somerville MA, US
Mark Joseph MULVIHILL - Sudbury MA, US
Elena S. KOLTUN - Foster City CA, US
Adrian L. GILL - Menlo Park CA, US

International Classification:

A61K 31/504
C07D 498/18
C07D 487/18
C07D 498/22
A61K 45/06

Abstract:

The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.

US Patent:

20190185484, Jun 20, 2019

Filed:

Mar 5, 2019

Appl. No.:

16/293410

Inventors:

- Cambridge MA, US
Juergen Ramharter - Vienna, AT
Henry Efrem Pelish - Newton MA, US
Brian Bor-Jen Liau - Belmont MA, US
Jae Young Ahn - Boston MA, US

Assignee:

President and Fellows of Harvard College - Cambrdge MA

International Classification:

C07D 493/08
C07K 16/26
C07K 14/575
C07D 493/22
C07D 519/00

Abstract:

Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof.Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the □-catenin pathway, methods of modulating STAT 1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.

US Patent:

20190062340, Feb 28, 2019

Filed:

Dec 21, 2016

Appl. No.:

16/078569

Inventors:

- Cambridge MA, US
Henry Efrem PELISH - Cambridge MA, US
Jae Young AHN - Cambridge MA, US

Assignee:

President and Fellows of Harward College - Cambridge MA

International Classification:

C07D 493/08
A61P 37/06
A61P 35/02

Abstract:

Specific cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hERG activity, and/or other pharmacological properties which make them stand out among the class of cortistatins as superior candidates for human administration.

US Patent:

20180369230, Dec 27, 2018

Filed:

Jun 22, 2018

Appl. No.:

16/016242

Inventors:

- Cambridge MA, US
Henry Efrem Pelish - Cambridge MA, US
Ioana Ilinca Nitulescu - Cambridge MA, US
Jae Young Ahn - Cambridge MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 31/4725
A61P 35/02

Abstract:

The invention relates to methods to to treat patients with specific Cortistatin analogs.

US Patent:

20180319814, Nov 8, 2018

Filed:

May 16, 2018

Appl. No.:

15/981575

Inventors:

- Cambridge MA, US
Juergen Ramharter - Vienna, AT
Henry Efrem Pelish - Newton MA, US
Brian Bor-Jen Liau - Belmont MA, US
Jae Young Ahn - Boston MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C07D 493/08
C07D 519/00
C07K 16/26
C07K 14/575
C07D 493/22

Abstract:

Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof.Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the -catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.

US Patent:

20170029435, Feb 2, 2017

Filed:

Jun 24, 2016

Appl. No.:

15/192629

Inventors:

- Cambridge MA, US
Juergen Ramharter - Vienna, AT
Henry Efrem Pelish - Newton MA, US
Brian Bor-Jen Liau - Belmont MA, US
Jae Young Ahn - Boston MA, US

International Classification:

C07D 493/08
C07D 519/00

Abstract:

Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof.Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the □-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.